CTL019

BIOLOGICAL7 trials

Conditions

Acute Lymphoblastic LeukemiaB-Cell Acute Lymphoblastic LeukemiaB-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaLeukemiaLymphomaNon Hodgkin LymphomaOff-label Indications

Phase 2

Study of Efficacy and Safety of CTL019 in Adult ALL Patients

WithdrawnNCT02167360

Abramson Cancer Center at Penn MedicineB-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia

Start: 2016-06-30Updated: 2017-02-14

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

CompletedNCT02435849

Novartis PharmaceuticalsB-cell Acute Lymphoblastic Leukemia

Start: 2015-04-08End: 2022-11-17Updated: 2024-02-13

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Active, not recruitingNCT03876769

Novartis PharmaceuticalsB-Cell Acute Lymphoblastic Leukemia

Start: 2019-06-24End: 2027-10-19Updated: 2026-08-19

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

TerminatedNCT04161118

University of CologneNon Hodgkin Lymphoma

Start: 2021-05-12End: 2023-02-24Updated: 2023-05-06

Phase 3

Phase III B in Acute Lymphoblastic Leukemia

CompletedNCT03123939

Novartis PharmaceuticalsAcute Lymphoblastic Leukemia

Start: 2017-04-24End: 2020-10-13Updated: 2021-07-21

Study of Out of Specification for Tisagenlecleucel

RecruitingNCT04094311

Novartis PharmaceuticalsB-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma

Start: 2019-11-21End: 2027-03-31Target: 200Updated: 2026-09-15

Unknown Phase

Managed Access Programs for CTL019, Tisagenlecleucel

NCT03601442

Novartis PharmaceuticalsLeukemia, Lymphoma, Off-label Indications

Updated: 2026-04-23

Journal of Clinical Oncology2026-07-29

Tisagenlecleucel (tisa-cel) in pediatric and young adult patients with high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) and minimal residual disease (MRD) at the end of frontline consolidation (EOC).

Journal of Clinical Oncology2026-05-27

Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial.

2025-04-181 citations

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Blood2023-11-024 citations

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial

Journal of Clinical Oncology2022-11-18310 citations

ANÁLISE DAS REAÇÕES ADVERSAS AO TISAGENLECLEUCEL: UMA REVISÃO DOS PRINCIPAIS ESTUDOS CLÍNICOS

Hematology Transfusion and Cell Therapy2022-10-01

S112: TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FINAL ANALYSES FROM THE ELIANA STUDY

HemaSphere2022-06-0135 citations

Impact of socioeconomic status on survival after CD19 CART therapy.

Journal of Clinical Oncology2022-06-01

Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.

2022-04-1426 citations

Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL

Blood2021-11-053 citations

Tisagenlecleucel Leukapheresis and Manufacturing Outcomes in Patients Less Than 3 Years of Age with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood2021-11-052 citations

Primary Progression on Frontline Therapy for Diffuse Large B-Cell Lymphoma Is Associated with a Poor Outcome Despite Subsequent CD19 Targeted CAR T-Cell Therapy

Blood2021-11-05

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma

Blood Advances2021-08-2528 citations

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

Journal for ImmunoTherapy of Cancer2021-08-0161 citations

Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy

Blood Advances2021-01-2556 citations

Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)

Blood2020-11-0538 citations

Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release

Blood2020-11-048 citations

CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL).

Journal of Clinical Oncology2020-05-2018 citations

Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).

Journal of Clinical Oncology2020-05-2013 citations

Immunotherapeutic Approaches in Acute Leukemias

Oncology Times2019-11-261 citations

18 more papers not shown

CTL019

Sponsors

Conditions

Phase 2

Phase 3

Unknown Phase

Related Papers